Ryvu Therapeutics presents its Development Plans for 2022-2024, aims to accelerate its mission
EIB to support Ryvu Therapeutics’ discovery, research and development of new cancer treatments with €22 million
Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board
What we do
We challenge current treatment paradigms
At Ryvu, we develop therapeutics that address clinical limitations of current treatments in oncology.
Our pipeline includes candidates with differentiated properties from kinase, synthetic lethality, and immuno-oncology programs.
Ryvu Therapeutics (Selvita Oncology) was founded in 2007. Since 2014, the company has been listed on Warsaw Stock Exchange under the ticker RVU.
Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees.See More